{"id":"https://openalex.org/W1490735293","doi":"https://doi.org/10.1158/1538-7445.am2014-3711","title":"Abstract 3711: Erk inhibition as a therapeutic option for the treatment of Raf- and Mek- inhibitor resistant tumors","display_name":"Abstract 3711: Erk inhibition as a therapeutic option for the treatment of Raf- and Mek- inhibitor resistant tumors","publication_year":2014,"publication_date":"2014-10-01","ids":{"openalex":"https://openalex.org/W1490735293","doi":"https://doi.org/10.1158/1538-7445.am2014-3711","mag":"1490735293"},"language":"en","primary_location":{"id":"doi:10.1158/1538-7445.am2014-3711","doi":"https://doi.org/10.1158/1538-7445.am2014-3711","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2014-3711","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","is_traditional":false,"indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5062400180","display_name":"Irene Seipelt","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210142512","display_name":"Aeterna Zentaris (Germany)","ror":"https://ror.org/03v0txq34","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210142512"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Irene Seipelt","raw_affiliation_strings":["1Aeterna Zentaris GmbH, Frankfurt, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Aeterna Zentaris GmbH, Frankfurt, Germany;","institution_ids":["https://openalex.org/I4210142512"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5091020854","display_name":"Peter M. Schmidt","orcid":"https://orcid.org/0000-0003-1340-9086","observed_orcids":["https://orcid.org/0000-0003-1340-9086"]},"institutions":[{"id":"https://openalex.org/I4210142512","display_name":"Aeterna Zentaris (Germany)","ror":"https://ror.org/03v0txq34","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210142512"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Peter Schmidt","raw_affiliation_strings":["1Aeterna Zentaris GmbH, Frankfurt, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Aeterna Zentaris GmbH, Frankfurt, Germany;","institution_ids":["https://openalex.org/I4210142512"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5088478309","display_name":"Helene Maerzhaeuser","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I114112103","display_name":"Leibniz University Hannover","ror":"https://ror.org/0304hq317","country_code":"DE","type":"education","lineage":["https://openalex.org/I114112103"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Helene Maerzhaeuser","raw_affiliation_strings":["2Leibniz University, Hannover, Germany"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"2Leibniz University, Hannover, Germany","institution_ids":["https://openalex.org/I114112103"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103421080","display_name":"Matthias Gerlach","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210142512","display_name":"Aeterna Zentaris (Germany)","ror":"https://ror.org/03v0txq34","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210142512"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Matthias Gerlach","raw_affiliation_strings":["1Aeterna Zentaris GmbH, Frankfurt, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Aeterna Zentaris GmbH, Frankfurt, Germany;","institution_ids":["https://openalex.org/I4210142512"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5081641655","display_name":"Kai Jung","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210142512","display_name":"Aeterna Zentaris (Germany)","ror":"https://ror.org/03v0txq34","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210142512"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Kai Jung","raw_affiliation_strings":["1Aeterna Zentaris GmbH, Frankfurt, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Aeterna Zentaris GmbH, Frankfurt, Germany;","institution_ids":["https://openalex.org/I4210142512"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5068076991","display_name":"Tilmann Schuster","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I4210142512","display_name":"Aeterna Zentaris (Germany)","ror":"https://ror.org/03v0txq34","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210142512"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Tilmann Schuster","raw_affiliation_strings":["1Aeterna Zentaris GmbH, Frankfurt, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Aeterna Zentaris GmbH, Frankfurt, Germany;","institution_ids":["https://openalex.org/I4210142512"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5074434713","display_name":"Michael Teifel","orcid":"https://orcid.org/0009-0006-6635-8517","observed_orcids":["https://orcid.org/0009-0006-6635-8517"]},"institutions":[{"id":"https://openalex.org/I4210142512","display_name":"Aeterna Zentaris (Germany)","ror":"https://ror.org/03v0txq34","country_code":"DE","type":"company","lineage":["https://openalex.org/I4210142512"]}],"countries":["DE"],"is_corresponding":false,"raw_author_name":"Michael Teifel","raw_affiliation_strings":["1Aeterna Zentaris GmbH, Frankfurt, Germany;"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"1Aeterna Zentaris GmbH, Frankfurt, Germany;","institution_ids":["https://openalex.org/I4210142512"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":2,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":0,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"74","issue":"19_Supplement","first_page":"3711","last_page":"3711"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11533","display_name":"Melanoma and MAPK Pathways","score":0.9990000128746033,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10169","display_name":"Protein Kinase Regulation and GTPase Signaling","score":0.0005000000237487257,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12104","display_name":"Protein Tyrosine Phosphatases","score":9.999999747378752e-05,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/erk-inhibitor","display_name":"ERK inhibitor","score":0.8289999961853027},{"id":"https://openalex.org/keywords/mapk-signaling","display_name":"MAPK signaling","score":0.8859999775886536},{"id":"https://openalex.org/keywords/raf-inhibitor-resistance","display_name":"RAF inhibitor resistance","score":0.8889999985694885},{"id":"https://openalex.org/keywords/mek-inhibitor-resistance","display_name":"MEK inhibitor resistance","score":0.9959999918937683},{"id":"https://openalex.org/keywords/brafv600e","display_name":"BrafV600E","score":0.8370000123977661},{"id":"https://openalex.org/keywords/combination-therapy","display_name":"combination therapy","score":0.652999997138977},{"id":"https://openalex.org/keywords/hct116-cells","display_name":"HCT116 cells","score":0.8109999895095825},{"id":"https://openalex.org/keywords/mda-mb-231-cells","display_name":"MDA-MB-231 cells","score":0.984000027179718},{"id":"https://openalex.org/keywords/antiproliferative-activity","display_name":"antiproliferative activity","score":0.8389999866485596}],"concepts":[{"id":"https://openalex.org/C57074206","wikidata":"https://www.wikidata.org/wiki/Q14197552","display_name":"MAPK/ERK pathway","level":3,"score":0.8635590076446533},{"id":"https://openalex.org/C502942594","wikidata":"https://www.wikidata.org/wiki/Q3421914","display_name":"Cancer research","level":1,"score":0.622672438621521},{"id":"https://openalex.org/C184235292","wikidata":"https://www.wikidata.org/wiki/Q421851","display_name":"Kinase","level":2,"score":0.6056883335113525},{"id":"https://openalex.org/C2781249067","wikidata":"https://www.wikidata.org/wiki/Q17142288","display_name":"MEK inhibitor","level":4,"score":0.5912148952484131},{"id":"https://openalex.org/C166342909","wikidata":"https://www.wikidata.org/wiki/Q845326","display_name":"Allosteric regulation","level":3,"score":0.46383580565452576},{"id":"https://openalex.org/C143065580","wikidata":"https://www.wikidata.org/wiki/Q3285695","display_name":"Mutant","level":3,"score":0.4332631230354309},{"id":"https://openalex.org/C97029542","wikidata":"https://www.wikidata.org/wiki/Q281417","display_name":"Protein kinase A","level":3,"score":0.4181656837463379},{"id":"https://openalex.org/C62112901","wikidata":"https://www.wikidata.org/wiki/Q189159","display_name":"Cell growth","level":2,"score":0.4150451719760895},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.36034834384918213},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.34315040707588196},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.3427339494228363},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.1649591028690338},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.13278087973594666},{"id":"https://openalex.org/C55493867","wikidata":"https://www.wikidata.org/wiki/Q7094","display_name":"Biochemistry","level":1,"score":0.10823136568069458},{"id":"https://openalex.org/C104317684","wikidata":"https://www.wikidata.org/wiki/Q7187","display_name":"Gene","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1158/1538-7445.am2014-3711","doi":"https://doi.org/10.1158/1538-7445.am2014-3711","is_oa":false,"landing_page_url":"https://doi.org/10.1158/1538-7445.am2014-3711","pdf_url":null,"source":{"id":"https://openalex.org/S168522863","display_name":"Cancer Research","issn_l":"0008-5472","issn":["0008-5472","1538-7445"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320273","host_organization_name":"American Association for Cancer Research","host_organization_lineage":["https://openalex.org/P4310320273"],"host_organization_lineage_names":["American Association for Cancer Research"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Cancer Research","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9537000060081482}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2077914269","https://openalex.org/W2318505167","https://openalex.org/W2787684716","https://openalex.org/W4389239866","https://openalex.org/W2560903486","https://openalex.org/W2795116596","https://openalex.org/W2003360338","https://openalex.org/W1982495603","https://openalex.org/W2129370444","https://openalex.org/W2142859055"],"abstract_inverted_index":{"Abstract":[0],"The":[1],"MAPK":[2,58,200,253],"pathway":[3,59,201],"represents":[4],"a":[5,107,207,250,337],"prime":[6],"target":[7,66],"for":[8,209,225,293,340,362],"therapeutic":[9,211,223,338],"intervention":[10],"in":[11,42,90,132,142,155,168,182,217,249],"cancer.":[12],"Recent":[13],"approvals":[14],"of":[15,31,56,94,140,184,193,234,252,271,281,290,304,343,353,358],"B-Raf":[16,143,235],"and":[17,25,36,45,60,80,102,110,125,149,173,199,227,236,257,262,300,306,345],"Mek":[18,37,81,103,130,169,185,248],"inhibitors":[19,38,88,131,216,274],"lead":[20],"to":[21,33,62,65,74,100,129,157,221,265],"exciting":[22],"antitumor":[23],"activities":[24],"survival":[26],"benefits.":[27],"However":[28],"the":[29,54,57,63,67,118,126,272,288,341,354,359],"observation":[30],"resistance":[32,128,254],"such":[34],"Raf":[35,79,101,119,159,246],"has":[39],"been":[40,179],"documented":[41],"both":[43],"clinical":[44],"preclinical":[46],"trials.":[47],"These":[48],"phenomena":[49],"stimulated":[50],"further":[51],"research":[52,285],"into":[53],"regulation":[55],"led":[61],"suggestion":[64],"downstream":[68,233],"kinase":[69,284,302],"Erk,":[70],"as":[71,73,336],"well":[72,180],"combine":[75],"its":[76],"targeting":[77,238,245],"with":[78],"inhibitors.":[82,104,160],"Here":[83],"we":[84,162],"report":[85],"that":[86,97,164,229],"Erk":[87,114,215,230,239,273,295,305,334],"result":[89],"efficient":[91],"growth":[92],"inhibition":[93,299,335],"tumor":[95,133,152],"cells":[96,176],"are":[98,310],"resistant":[99,171,348],"AEZS-134":[105,141,165,256],"-":[106,116],"highly":[108],"potent":[109,137,261],"selective":[111,263],"ATP":[112],"competitive":[113],"inhibitor":[115,120,170,347],"overcomes":[117],"induced":[121],"paradoxical":[122],"cell":[123,153],"activation":[124],"aquired":[127],"cells.":[134],"We":[135],"demonstrate":[136],"antiproliferative":[138],"activity":[139],"wildtype,":[144],"B-RafV600E":[145],"mutant,":[146],"Ras":[147],"wildtype":[148],"K-Ras":[150,194],"mutant":[151],"lines":[154],"comparison":[156],"common":[158],"Furthermore":[161],"show":[163],"is":[166,231,278],"efficacious":[167],"Hct116":[172],"MDA":[174],"MB231":[175],"which":[177],"have":[178],"characterized":[181],"terms":[183],"F129L":[186],"allosteric":[187],"binding":[188],"pocket":[189],"mutation,":[190],"varying":[191],"degrees":[192],"amplification,":[195],"cellular":[196],"proliferation":[197],"assays":[198],"phosphorylation":[202],"studies.":[203],"Our":[204],"data":[205],"provide":[206,260],"rational":[208],"new":[210],"opportunities":[212],"by":[213,275,313],"using":[214],"oncology.":[218],"In":[219],"order":[220],"maximize":[222],"benefit":[224],"patients":[226],"considering":[228],"directly":[232],"Mek,":[237],"may":[240],"be":[241],"more":[242],"effective":[243],"than":[244],"or":[247],"variety":[251],"settings.":[255],"related":[258],"compounds":[259,292,309],"tools":[264],"help":[266],"address":[267],"this":[268],"question.":[269],"Development":[270],"\u00c6terna":[276],"Zentaris":[277],"integral":[279],"part":[280],"our":[282,314],"inhouse":[283],"program":[286],"comprising":[287],"investigation":[289],"different":[291],"single":[294,297],"inhibition,":[296],"PI3K":[298],"dual":[301],"inhibitions":[303],"PI3K.":[307],"All":[308],"exclusively":[311],"synthesized":[312],"medicinal":[315],"chemistry":[316],"department.":[317],"Citation":[318],"Format:":[319],"Irene":[320],"Seipelt,":[321],"Peter":[322],"Schmidt,":[323],"Helene":[324],"Maerzhaeuser,":[325],"Matthias":[326],"Gerlach,":[327],"Kai":[328],"Jung,":[329],"Tilmann":[330],"Schuster,":[331],"Michael":[332],"Teifel.":[333],"option":[339],"treatment":[342],"Raf-":[344],"Mek-":[346],"tumors.":[349],"[abstract].":[350],"In:":[351],"Proceedings":[352],"105th":[355],"Annual":[356],"Meeting":[357],"American":[360],"Association":[361],"Cancer":[363,374],"Research;":[364],"2014":[365],"Apr":[366],"5-9;":[367],"San":[368],"Diego,":[369],"CA.":[370],"Philadelphia":[371],"(PA):":[372],"AACR;":[373],"Res":[375],"2014;74(19":[376],"Suppl):Abstract":[377],"nr":[378],"3711.":[379],"doi:10.1158/1538-7445.AM2014-3711":[380]},"counts_by_year":[],"updated_date":"2026-09-23T05:00:35.095934","created_date":"2016-06-24T00:00:00"}